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JOHANN DUSLEAG, MD
Graz, Austria
The efficacy of benazepril, metoprolol OROS and their com-
bination was evaluated in 29 patients (42 to 74 years of age)
with chronic stable angina and documented coronary artery
disease in a placebo-controlled, double-blind, crossover trial
using serial quantitated exercise testing and ambulatory elec-
trocardiographic (ECG) monitoring. The mean (±SEM) ex-
ercise time was 8.5 ± 0.7 min with placebo, 8.3 ± 0.6 min
(95% confidence interval [CI] -1.06 to 0.54) with benazepril,
9.4 ± 0.5 min (95% CI -0.32 to 2.14) with metoprolol OROS
and 9.6 ± 0.5 min (95% CI -0.25 to 2.47) with the combi-
nation of benazepril and metoprolol OROS. The mean exer-
cise time to the development of 1 mm ST segment depression
was prolonged from 6.0 ± 0.6 min with placebo to 6.3 ± 0.6
min (95% CI -0.93 to 1.45) with benazepril, 7.9 ± 0.5 min
(95% CI 0.83 to 3.0) with metoprolol OROS and 8.1 ± 0.6
min (95 % CI 0.88 to 3.29) with the combination of benazepril
and metoprolol OROS.
Benazepril did not alter the rest or maximal heart rate,
whereas metoprolol OROS alone and in combination sig-
nificantly lowered the heart rate at rest and during maximal
exercise. Systolic blood pressure at rest was nonsignifi-
cantly reduced, whereas diastolic blood pressure was low-
ered significantly by all treatments in comparison with
placebo. At maximal exercise, only metoprolol OROS,
whether given alone or in combination with benazepril, was
able to blunt significantly systolic blood pressure and
rate-pressure product.
Angiotensin-converting enzyme inhibitors are now well es-
tablished and accepted for the treatment of hypertension and
congestive heart failure, However. their usefulness in coro-
nary artery disease is not well explored, A pilot investigation
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During ambulatory ECG monitoring, heart rate was
lowered throughout the 24 h period with metoprolol OROS
but not with benazepriI. Total episodes of ST segment
depression in 24 h were 221 with placebo, 160 (95% CI
-3.72 to 1.28) with benazepril, 136 (95% CI -4.68 to
-0.89) with metoprolol OROS and 150 (95% CI -5.35 to
0.78) with the combination of benazepril and metoprolol
OROS. Similarly, total ischemic burden was 1,549 min
with placebo, which was reduced to 879 min (95% CI
-48.28 to 1.92) with benazepril, 807 min (95% CI -44.87
to -6.63) with metoprolol OROS and 828 min (95% CI
-49.63 to -0.37) with the combination of these.
In conclusion, metoprolol OROS is an effective anti-
ischemic agent. Benazepril did not produce any clinical
benefit in terms of exercise test variables. However, a
clinically meaningful although statistically nonsignificant
reduction in severity and number of ischemic episodes and
duration of ST segment depression during ambulatory ST
segment monitoring was observed. Because about 97% of
ischemic episodes were silent, the findings suggest that
benazepril might be beneficial in improving silent myocar-
dial ischemia. Both drugs were well tolerated when admin-
istered singly or together. The data also confirm that
benazepril did not impair the anti-ischemic effects of meto-
prololOROS.
(J Am Coli CardioI1990;16:948-56)
(1,2) of captopril in patients with angina and concomitant
essential hypertension suggests that this class of drugs might
be beneficial in the management of patients with angina
pectoris, Angiotensin II is a potent vasoconstrictor of the
systemic and coronary arteries that increases the vascular
tone of the large conductive coronary vessels. especially
during sodium depletion (3), but it has little effect on the
small resistant coronary vessels and possesses positive
inotropic effects, Therefore. increased angiotensin II pro-
duction would further compromise the ischemic myocar-
dium by reducing oxygen supply while increasing myocar-
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dial oxygen demand as a result of both the increased
inotropic state and increased afterload (3-5).
Angiotensin-converting enzyme inhibitors reduce blood
pressure without producing reflex tachycardia and thereby
lower the heart rate-blood pressure product, which is a
reflection of a decrease in myocardial oxygen consumption
(3), and this effect can be beneficial in patients with angina
pectoris in whom the primary aim of medical therapy is to
improve myocardial oxygen supply and reduce myocardial
oxygen consumption. Although the reason for the lack of
reflex tachycardia with angiotensin-converting enzyme in-
hibitors is not fully understood, it has been suggested that it
might be due to a sympatholytic or vagomimetic effect
during angiotensin-converting enzyme inhibition. It has also
been suggested that angiotensin-converting enzyme inhibi-
tors are coronary vasodilators (6,7). In view of the suggested
mechanisms, such a study was undertaken in patients with
coronary artery disease and established chronic stable an-
gina pectoris to evaluate the safety and antianginal and
anti-ischemic effects of the new angiotensin-converting en-
zyme inhibitor benazepril in comparison with the beta-
adrenergic blocking agent metoprolol OROS.
Methods
Study patients. Thirty-one patients (28 men and 3
women, 42 to 74 years of age) with established grade II or III
stable effort-induced angina pectoris (8) were recruited for
the study. Twenty-five patients were nonsmokers, five were
smokers and one patient's smoking status could not be
established. The duration of angina ranged from 4 to 120
months (mean 29.8). Coronary artery disease was confirmed
in all 31 patients with selective coronary arteriography,
which demonstrated>75% occlusion of one or more major
coronary arteries. The left ventricular function as assessed
by ejection fraction was normal in all patients (mean 65%,
range 53% to 80%). Ten patients had previous myocardial
infarction.
The previous antianginal treatment was nifedipine (n = I
patient), verapamil (n = 3), diltiazem (n = 7), gallopamil (n
= 2), sotalol (n = 1), atenolol (n = 2), metoprolol (n = 7) and
isosorbide mononitrate (n = 15). All patients were gradually
and completely withdrawn from their current antianginal
treatment other than sublingual nitroglycerin to control
anginal pain for at least I week before the start of the study.
The study was approved by the Hospital Ethical Committee
and all patients gave informed consent after the nature and
purpose of the study were explained. All patients were
required to fulfill the following inclusion and exclusion
criteria, which have been described previously (9-11).
Inclusion criteria. Patients were required to develop an-
gina on treadmill exercise testing accompanied by 2: I mm
horizontal or downsloping ST segment depression at the J
point in one of the monitored bipolar electrocardiographic
(ECG) leads CMs and CCs' If the ST segment slope was
:50.1 mVIs, they were required to have 2: 1 mm ST segment
depression. If the ST slope was> I mVIs, the patients were
excluded, whereas for those whose ST slope was between
0.1 mV and I mVIs, 2:2 mm ST segment depression was
required. The patients were required to have had for 2:4
months symptomatic stable angina that was relieved by rest
and sublingual nitroglycerin with an average incidence of
four anginal attacks per week. Patients also had to have
unequivocal evidence of coronary artery disease by selective
coronary arteriography (that is, 2:75% narrowing of one or
more coronary arteries) or previous myocardial infarction.
All patients were required to be physically capable of
undertaking regular exercise tests.
Exclusion criteria. Patients were excluded from the study
if they were receiving any drug likely to influence heart rate
or ST segment level. such as digitalis or diuretic drugs, or if
they had a rest blood pressure > 1701105 mm Hg, left
ventricular hypertrophy or bundle branch block. Patients
with a history of recent myocardial infarction within the
preceding 4 months, unstable angina, clinical congestive
heart failure, bronchial asthma, peripheral vascular disease,
insulin-dependent diabetes mellitus or the labile ST-T syn-
drome were also excluded. as were patients>75 years of age
and women of childbearing age. Any patient not developing
classic anginal pain and 2: I mm ST segment depression
during the initial control test or who had an exercise time
during the placebo run-in test >8 min or exercise time
variability on two control tests 2:20%, or both, was ex-
cluded.
Trial design. All patients were withdrawn from their
current antianginal treatment gradually and completely and
were maintained on sublingual nitroglycerin alone to control
anginal pain for 2: 1 week before performing a baseline
control exercise test. Thereafter, all patients were entered in
a single-blind placebo run-in period of I week. Subse-
quently, they were randomly allocated in equal numbers to a
randomized treatment sequence (Fig. I) (using a latin square
design) of the following four trial treatments using a double-
dummy technique: I) Benazepril, 20 mg twice daily: one 20
mg benazepril tablet and one metoprolol OROS placebo
tablet in the morning and in the evening. 2) Metoprolol
OROS, 14/190 mg (release rate/total dose) once daily: one
active tablet of metoprolol OROS and one placebo tablet of
benazepril in the morning and one placebo tablet of
benazepril and one placebo tablet of metoprolol OROS in the
evening. 3) Benazepril. 10 mg twice daily, plus metoprolol
OROS, 14/190 mg once daily: one active tablet of each in the
morning and one active tablet of benazepril and one placebo
tablet of metoprolol OROS in the evening. 4) Placebo: one
placebo tablet of benazepril and one placebo tablet of
metoprolol OROS in the morning and in the evening.
The trial medication was administered twice daily. The
double-blind treatment periods were of 3 weeks' duration.
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Figure 1. Trial design. Numbers above the line represent weeks (-2
to 13) and those below the line visits (1 to 6). B = 20 mg benazepril
twice daily; B+ M= 10 mg benazepril twice daily and metoprolol
OROS 14/190 mg once daily; M= metoprolol OROS 14/190 mg once
daily; P = placebo.
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At the end of each double-blind treatment period, a symp-
tom-limited treadmill exercise test was performed in the
morning without the administration of the trial medication to
allow evaluation of the effect 12 h after administration of
benazepril and 24 h after administration of metoprolol
OROS. Ambulatory ECG monitoring was performed for 24 h
at the end of each treatment period.
Assessment. The patients maintained a detailed diary
of adverse effects, anginal attacks and sublingual nitroglyc-
erin consumption. They were asked not to use sublingual
nitroglycerin prophylactically. Objective evaluation was
achieved by performing serial maximal symptom-limited
treadmill exercise tests (9,10) as already described. All
exercise tests were performed in the morning ~2 h after a
light breakfast and without administration of the morning
dose of active or inactive study medication. The patients
rested comfortably in the exercise laboratory for ~30 min
before each test and were asked not to smoke or take
sublingual nitroglycerin tablets on the morning of the test.
Exercise testing. Exercise tests were performed on an
electrically braked treadmill (Trottoir Roland, Enraf Nonius)
in a temperature-controlled laboratory (20° to 24°C) by the
same investigator at the same time of the day. During the
pretrial screening period, one to two familiarizing tests were
performed for technical training and physiologic adaptation
of the patient in case he or she was not familiar with the
nature of the test situation. A multistage symptom-limited
exercise test employing increasing work loads with each
stage of 3 min duration was performed according to the
Bruce protocol (12) (Table I). The speed and gradient for
each stage were fixed by the protocol. At the end of each
stage, systolic blood pressure was recorded with a mercury
sphygmomanometer. The six lead ECG was continuously
Table 1. Bruce Treadmill Exercise Protocol
Speed Grade of Duration of Cumulative
in mph Elevation Each Stage Duration
Stage (km/h) ('If) (min) (min)
1.7 C.7) 10 3
2.5 (4.0) 12 6
3 3.4 (5.5) 14 9
4 4.2 (6.8) 16 12
5 5.U (8.0) 18 15
6 5.5 (8.8) 20 18
monitored and the ST segment level and heart rate were
recorded at rest. every minute during exercise and for 5 min
thereafter. The end points considered for possible termina-
tion of the exercise test were anginal pain, breathlessness,
fatigue, the appearance of a life-threatening arrhythmia, a
decrease in systolic blood pressure ~20 mm Hg with increas-
ing work load or excessive increase in blood pressure (for
example. systolic blood pressure 220 mm Hg and diastolic
blood pressure ~125 mm Hg). However, in this study, all
exercise tests except one were terminated because of mod-
erate to severe chest pain of a magnitude that would have
limited the patient's daily activities. The standard safety
precautions as outlined by the American Heart Association
(13) for exercise testing laboratories were followed.
Ambulatory ECG monitoring. Patients underwent 24 h
Holter monitoring after exercise testing. After appropriate
preparation of the skin. pregelled disposable electrodes were
applied using a bipolar lead system. Two bipolar ECG leads
(CM 5 and CC 5 ) were recorded utilizing a two channel 24 h
tape recorder (Reynolds Tracker TRIB) (10,11.14). The ST
segment changes induced by position (prone, supine. left
side. right side, sitting and standing) or hyperventilation
were investigated. Patients were instructed to perform their
usual daily activities during the 24 h monitoring period. They
were asked to keep a detailed diary of all activities and
symptoms. Ambulatory ECG tapes were analyzed (14) by a
dynamic electrocardioscanner (Reynolds Pathfinder III).
ST segment analysis. Calibrated tapes were replayed at 60
times normal speed under the control of the operator. A
reference point within the PO segment. an ST-I point at the
J point and an ST-2 point 0.06 to 0.08 s thereafter were
preselected by the operator at the beginning of the playback.
The difference between the ST-I and ST-2 point and the
reference point and heart rate were averaged over a period of
8 to 64 cycles and simultaneously plotted on a strip chart
recorder together with the changes in slope and area. ST
segment elevations resulted in positive deflections and ST
segment depressions in negative deflections of the ST trend.
ST-I and ST-2 deflections were considered significant when
they were> 100 f.LV. slope changes when < I f.LVIs and area
changes when> 10 f.LVis. A paper speed of 0.7 to 6 cmlh was
selected for the trend recordings. Ventricular ectopic beats
Double-blind Treatment PeriodsWash,out Placebo
Period Period
I I
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Exercise time (min)
I mm ST depression time Iminl
Maximal ST depression (mm)
Heart rate at rest (beats/min)
Heart rate at maximal exercise
Ibeats/min)
Systolic BP at rest (mm Hg)
Diastolic BP at rest Imm Hg)
Systolic BP at maximal exercise
Imm Hg)
Rate-pressure product at
maximal exercise lunits)
Placebo
8.5 ± 0.7
6.0 ± 0.6
1.7 ± 0.2
80 ± 3
129 ± 3
138.5 ± 4.4
87.3 ± 1.6
172.6 ± 3.8
224.2 ± 8.8
Benazepril 195'7r CI)
8.3 ± 0.6 (-1.06 to 0.54)
6.3 ± 0.6 (-0.93 to 1.45)
1.5 ± 0.2 (-0.54 to 0.10)
79 ± 31-6.15 to 3.98)
127 ± 41-7.93 to 3.84)
131.1 ± 4.1 (- 16.55 to 1.77)
81.5 ± 1.81-9.8 to -1.51
162.8 ± 3.4 1- 20.72 to 1.161
207.9 ± 8.21-37.15 to 4.621
Metoprolol OROS 195'7r CI)
9.4 ± 0.5 (-0.32 to 2.141
7.9 ± 0.5 10.83 to 3.0)
1.5 ± 0.2 (-0.65 to 0.211
65 ± 2 (-21.51 to -9.54)
107 ± 21-29.21 to -15.05)
129.8 ± 3.11-17.54 to 0.15)
82.9 ± 1.9 (-8.4 to -0.6)
160.4 ± 3.3 1- 20.6 to - 3.75)
172.5 ± 5.9 (-69.20 to - 34.26)
Benazepril + Metoprolol OROS
(95'7r CI)
9.6 ± 0.5 (-0.25 to 2.47)
8.1 ± 0.6 (0.88 to 3.29)
1.5 ± 0.2 (-0.51 to 0.(8)
61 ± 2 (-24.05 to -13.61)
106 ± 3 (-28.99 to -17.(9)
132.2 ± 4.1 1-13.21 to 0.60)
82.6 ± 1.8 (-8.7 to -0.61
163.0 ± 3.21-18.15 to -0.981
173.7 ± 6.1 (-67.03 to - 34.041
Data are expressed as mean values ± SEM. BP = blood pressure: 95'7r CI = 95'7r confidence interval. both upper and lower, of the mean differences between
active treatment and placebo: benazepril dosage is 20 mg twice daily: metoprolol OROS dosage is 14/190 mg once daily: benazepril + metoprolol OROS dosage
is benazepril 10 mg twice daily + metoprolol OROS 14/190 mg once daily.
were automatically excluded from ST segment analysis,
During each episode with ST segment deviation of > I mm.
the ECG was printed out at a paper speed of 25 mm/s. By
visual analysis. ST segment elevations and horizontal or
downsloping ST segment depressions of > I mm. persisting
for 2':60 s, were regarded as ischemic episodes. After auto-
matic analysis. all ECG strips showing episodes of ST
segment deviation were printed out and their duration and
maximal magnitude were measured.
Statistical analysis. All statistical analyses were per-
formed using the statistical analysis system (SAS. SAS
Institute). version 5.18. For statistical significance testing
(two-tailed tests). the significance level was set at 5%. The
confidence level was set at 95% for computing of confidence
limits or intervals for the differences between active treat-
ment and placebo. A confidence interval contains a real
treatment difference with a probability of I - a, where a is
the usual type I error and gives an idea of the likely spread
of values that could have occurred by chance. The relation
between confidence interval and significance test is the
following: if the confidence interval for the difference be-
tween two mean values contains the zero point. then the
significance test would be nonsignificant with a level of a and
vice versa. For example. if a 95% confidence interval for the
difference between mean exercise time to I mm ST depres-
sion in patients treated with metoprolol OROS and placebo
is 0.83 to 3.0, so that zero point is not included, then a
statistically significant difference with p < 0.05 (5%) is
shown.
All data were analyzed by an analysis of variance for the
patients. the visits. the treatments and the visit-treatment
interactions. For the variable heart rate at maximal exercise.
a treatment-visit interaction was observed (p = 0.0122), In
all other cases, this interaction was statistically nonsignifi-
cant. As one would expect for a crossover design. the patient
effect was significant in all cases. A visit effect could be
observed only for the variable heart rate at rest (p = 0.0154).
Results
Atotal of 31 patients (28 men and 3 women. 42 to 74 years
of age) were recruited for the study. One patient (Case 31)
withdrew his consent during the first treatment period and
one patient died suddenly at home during the first double-
blind treatment period. This latter patient was receiving
placebo: the exact cause of death could not be established
because the cardiologist in charge was not informed. It was
thought that the patient. who had triple vessel disease. died
of massive myocardial infarction. Therefore, only 29 pa-
tients successfully completed the study.
Protocol violators. Four patients were considered proto-
col violators because their exercise time during the initial
two control tests was either >8 min or the variability of
exercise time in two tests was >20%. Two patients took
sublingual nitroglycerin tablets before the exercise test and
their data could not be used for efficacy analysis. Therefore,
only 23 patients were analyzed for exercise test data. How-
ever. all 29 patients were analyzed for ambulatory ST
segment and heart rate data as well as tolerability and safety.
Exercise Test Results (Tahle 2)
Exercise time. All patients developed moderate to severe
anginal pain at maximal exercise during all exercise tests,
except one patient who discontinued the test because of
shortness of breath while receiving the combination of
benazepril and metoprolol OROS. The exercise time (mean
± SEM) was 8.5 ± 0.7 min with placebo and 8.3 ± 0.6 min
(95% confidence interval [CI] -1.06 to 0.54) with benazepril.
This increased to 9.4 ± 0.5 min (95% CI -0.32 to 2.14) with
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Table 3. Variables of Ambulatory Electrocardiographic Monitoring for 24 h in 29 Patients
Metoprolol OROS Benazepril + Metoprolol
Placebo Benazepril (957< CO (95% CO OROS (95% CO
Total episodes of ST segment 221 160 (-3.72 to 1.281 136 (-4.68 to -0.89) 150 (-5.35 to 0.78)
depression> 1 mm in 24 h
Total duration of ST segment 1.549 879 (-48.28 to 1.92) 807 (-44.87 to -6.63) 828 (-49.63 to -0.37)
depression in 24 h (min)
Mean maximal depth of ST segment 2.48 1.81 (-1.45 to 0.10) 1.81 (-1.08toO.311 1.41 (-1.01 to -0.11)
depression (mm)
Average heart rate during 24 h 75 ± 2 75 ± 2 (-4.5 to 3.9) 62 ± 2 (-16.6 to -8.7) 61 ± 2 (-18.5 to -10.5)
(beats/min)
Abbreviations and drug dosage as in Table 2.
metoprolol OROS and 9.6 ± 0.5 min (95% C1 -0.25 to 2.47)
with the combination of benazepril and metoprolol OROS.
Using analysis of variance. there was a statistically signifi-
cant treatment effect (p < 0.038), which was most probably
due to metoprolol OROS. However, this effect became
nonsignificant in comparison with placebo (p < 0.054). most
probably because of an unbalanced trial design.
ST segment changes. The mean exercise time to I mm ST
segment depression in lead CMs was 6.0 ± 0.6 min with
placebo. which increased to 6.3 ± 0.6 min (95% CI -0.93 to
1.45) with benazepril. 7.9 ± 0.5 min (95% CI 0.83 to 3.0) with
metoprolol OROS and 8.1 ± 0.6 min (95% CI 0.88 to 3.29)
with the combination of benazepril and metoprolol OROS.
Maximal ST segment depression in lead CMs at peak exer-
cise remained unaltered during the active treatment. proba-
bly because of increased exercise time.
Blood pressure, heart rate and rate-pressure product.
None of the treatments significantly altered systolic blood
pressure at rest as compared with placebo. However. dias-
tolic blood pressure was significantly reduced by 5.8 mm Hg
with benazepril (95% C1 -9.8 to -1.5). 4.4 mm Hg with
metoprolol OROS (95% CI -8.4 to -0.6) and 4.7 mm Hg
(95% CI -8.7 to -0.6) with the combination of benazepril
and metoprolol OROS. The systolic blood pressure at max-
imal exercise was only blunted significantly by metoprolol
OROS and the combination of benazepril and metoprolol
OROS. but not by benazepril alone. Heart rate at rest and
maximal exercise was significantly blunted by metoprolol
OROS and the combination of benazepril and metoprolol
OROS but not by benazepril alone. The rate-pressure prod-
uct of 224.2 ± 8.8 units on placebo was reduced to 207.9 ±
8.2 units (95% C1 - 37.15 to 4.62) on benazepriI, 172.5 ± 5.9
units (95% CI -69.20 to - 34.26) with metoprolol OROS and
173.7 ± 6.1 units (95% CI -67.03 to -34.04) with the
combination of benazepril and metoprolol OROS.
Anginal Attacks and Sublingual Nitroglycerin
Consumption
During the 3 week treatment period. 342 anginal attacks
were recorded with placebo; the number of attacks was
reduced to 326 with benazepril, 318 with metoprolol OROS
and 268 with the combination of benazepril and metoprolol
OROS. Similarly. the consumption of nitroglycerin tablets
was 174 with placebo and was reduced to 171 with
benazepriI, 128 with metoprolol OROS and 129 with the
combination of benazepril and metoprolol OROS. These
data were evaluated only descriptively and no statistical
tests were performed because some patients failed to return
or fill in the diary cards completely. However, it appears that
the changes observed during active treatment are neither
clinically relevant nor statistically significant.
Ambulatory ECG Monitoring (Table 3)
During 24 h ambulatory ECG monitoring, two leads (CMs
and CCs) were recorded. However, for analysis only one
lead (either CMs or CCs) that showed the greater number of
episodes of ST segment depression on placebo was chosen.
Thereafter. the same lead was kept constant for comparison
throughout the study in the same patient.
Mean hourly heart rate over 24 h. The average heart rate
over 24 h was significantly lower with metoprolol OROS and
the combination of benazepril and metoprolol OROS, but
not with benazepril alone as compared with placebo, respec-
tively. The mean hourly heart rate also remained lowered
throughout the 24 h period on metoprolol OROS treatment
(Fig. 2).
Total number of episodes of ST segment depression. The
total number of episodes (seen in either lead CMs or CCs)
(Fig. 3) with placebo treatment was 221 (range 2 to 25 per
patient). These decreased nonsignificantly with benazepril to
160 (95% CI -3.72 to 1.28). significantly with metoprolol
OROS to 136 (95% CI -4.68 to -0.89) and nonsignificantly
with the combination of benazepril and metoprolol OROS to
150 (95% C1 -5.35 to 0.78). During placebo treatment, 2.7%
of the episodes were symptomatic and 97.3% were asymp-
tomatic. With benazepriI, 9.4% were symptomatic and
90.6% were asymptomatic. With metoprolol OROS. 6.6%
were symptomatic and 93.4% were asymptomatic. With the
combination of benazepril plus metoprolol OROS, 4.7%
were symptomatic and 95.3% were asymptomatic.
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1.41 mm (95% CI -1.01 to -0.11) with the combination of
benazepril and metoprolol OROS.
Tolerance and Adverse Effects
Subjective tolerance was good to very good with all
treatments in all patients except one who reported poor
tolerance during placebo treatment. The mean body weight
was 77 kg with placebo and with benazepril, 77.3 kg with
metoprolol OROS and 77.1 kg with the combination of
benazepril and metoprolol OROS. During the placebo run-in
period one patient (Case 5) reported a transient skin rash that
was not attributed to the trial medication. No other side
effects were reported or observed in this study.
~R~~~~~~~~~~~~~P~~~~~~~~~ <¥ ....fS .............'l: ....ns ...." ....Vi ,~ " . ....tti ....OJ q,~ rt" ~ f},AJ
Time 01 day (Hours)
Discussion
Antianginal drugs and their evaluation. Angina pectoris
typically results from myocardial ischemia due to an imbal-
ance between the myocardial oxygen demand and supply
(15-18) and in most patients is caused by obstructive coro-
nary artery disease. The objective of drug therapy, there-
fore. is either to decrease those factors that increase myo-
cardial oxygen demand or decrease myocardial blood supply
(19-21). Three classes of drugs are now used for the treat-
ment and secondary prevention of chronic stable angina:
nitrates. beta-adrenergic blocking agents and calcium-
channel blocking drugs (19-26). It is vital that the pharma-
cology. comparative efficacy and unwanted effects profile of
the available antianginal drugs is fully understood to pre-
scribe effectively the appropriate medical therapy for pa-
tients with stable angina pectoris (19-21). Beta-blockers act
by reducing the myocardial oxygen demand by slowing the
heart rate at rest and during exercise (22-26). They also
lower systemic arterial pressure. particularly during exercise
(25), This class of drugs has negative inotropic effects and
may increase left ventricular size and filling pressure (24-
26). Beta-blockers also inhibit coronary vasodilation and
cause an increase in coronary vasomotor tone (24.27). Ob-
jective methods to evaluate antianginal drugs are essential if
the results are to be meaningful (9-11) because reduction of
the anginal attack rate and sublingual nitroglycerin consump-
tion as a sole criterion for antianginal efficacy is not sufficient
because these indexes are influenced by the marked variabil-
ity of the symptoms due to varying levels of activity and
changing emotional and environmental influences.
During the evaluation of any new drug. it is imperative
that I) the drug be compared with placebo under double-
blind conditions: 2) it be compared with the standard drugs
used for the same indication: and 3) its safety and efficacy
when given in combination with the standard drugs be
established. This study was undertaken to explore all three
possibilities. A multicrossover design with 3 week treatment
periods was used: I) benazepril was compared with placebo:
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Figure 3. Number of ischemic episodes 1ST depression) and dura-
tion of ischemia (in minutes) in 24 h on ambulatory electrocardio-
graphic monitoring. P-I = placebo in single-blind trial: other abbre-
viations as in Figure I.
Figure 2. Ambulatory hourly mean heart rate for 24 h during
administration of placebo. 20 mg benazepril twice daily (b.i.d.l.
14/190 mg metoprolol OROS once daily (o.d.). and the combination
of 10 mg benazepril twice daily and 14/190 mg melOprolol OROS
once daily.
Total duration of ST segment depression in 24 h (Fig. 3).
As seen on either lead CMs or CCs' the total duration
(ischemic burden) was 1,549 min (range 3 to 264 min/patient)
on placebo treatment. It was reduced nonsignificantly to 879
min (95% CI -48.28 to 1.92) with benazepril. significantly to
807 min (95% CI -44.87 to -6.63) with metoprolol OROS
and significantly to 828 min (95% CI -49.63 to -OJ7) with
the benazepril and metoprolol OROS combination.
Severity of episodes of S1 segment depression. The sever-
ity averaged 2.48 mm on placebo treatment. which was
reduced to 1.81 mm (95% CI - 1.45 to 0.10) with benazepril.
1.81 mm (95% CI -1.08 to OJI) with metoprolol OROS and
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2) benazepril was compared with a standard beta-blocker,
metoprolol OROS; and 3) the safety and efficacy of com-
bined treatment of benazepril and metoprolol OROS were
evaluated.
Benazepril hydrochloride, a new angiotensin-converting
enzyme inhibitor. This agent is a nonsulfhydryl, orally ac-
tive. selective inhibitor of angiotensin-converting enzyme
and is a prodrug. being deesterified to the free acid metabo-
lite benazeprilate. Like other angiotensin-converting en-
zyme inhibitors. it is a potent antihypertensive agent (28)
and its beneficial effects have been shown in patients with
heart failure (29). The usefulness of this class of angiotensin-
converting enzyme inhibitors in angina pectoris has not been
studied systematically. A few clinical studies (1,2.30-32)
using enalapril or captopril in a small number of patients with
angina pectoris have been performed with variable results.
However. their usefulness in ischemic heart disease has
been advocated at least theoretically (33,34) because angio-
tensin II is a potent vasoconstrictor that possesses positive
inotropic effects that could compromise the ischemic myo-
cardium by reducing oxygen supply while increasing myo-
cardial oxygen demand (3-5).
Angiotensin-converling enzyme inhibitors reduce left
ventricular diastolic pressure. aortic systolic pressure and
sympathetic drive (30). effects that should reduce myocar-
dial work and oxygen consumption. and therefore Ihat
should be useful in the treatment of angina. Other possible
mechanisms of angiotensin-converting enzyme inhibitors
include coronary vasodilation (6.7). which improves myo-
cardial blood supply and reduces blood pressure wilhout
inducing reflex tachycardia, thereby reducing rate-pressure
product. an index of myocardial oxygen demand 05-18,30).
To test the hypothesis that benazepril is useful in palients
with chronic stable angina, the higher dosage of benazepril
(20 mg twice daily) rather than the usual dosage (10 to 20 mg
once daily) in essential hypertension was chosen (28).
Metoprolol OROS, a new sustained-release formulation of
metoprolol fumarate. This new drug formulation (adminis-
tered once daily) was chosen as the comparative agent. In
clinical studies (35). metoprolol OROS has been shown to
possess similar antihypertensive (Research report June 1989:
unpublished observations. Ciba-Geigy) and antianginal ef-
fects as standard metoprolol. Metoprolol OROS consists of a
core of metoprolol fumarate surrounded by a semipermeable
membrane in which a minute orifice has been created with a
laser beam. This membrane allows water to enter. but does
not permit the larger molecules of metoprolol to escape. As
soon as water from the digestive tract penetrates through the
membrane into the interior of the system, metoprolol begins
to dissolve. The result is a saturated solution. the osmotic
pressure of which causes more water to diffuse into the core,
propelling an equal volume of metoprolol solution out
through the orifice. The osmotic and hence hydrostatic
pressure within the system is great enough to ensure that the
orifice is always flushed clear and cannot become blocked
(for example. by food particles). The process continues as
long as there is still some undissolved active substance in the
core of the system. Throughout this period (zero-order
release). constant delivery of metoprolol is maintained.
Afterwards. metoprolol is released in the form of a solution
that becomes more and more diluted until the osmotic
pressure within the system equals that outside it. During this
second phase. the release rate gradually diminishes. The
semipermeable membrane surrounding the core consists of
an inert cellulose derivative that is insoluble in water, gastric
juice and the alkaline intestinal milieu. After its transit
through the gut. it is excreted unchanged in the feces.
Comparative effects of benazepril and metoprolol OROS
during exercise. In this study, both benazepril and meto-
prolol OROS were well tolerated. whether given alone or in
combination. No clinically relevant biochemical abnormali-
ties were detected. During exercise testing, benazepril did
not produce any significant effects on exercise tolerance,
blood pressure. ST segment changes and heart rate. Only
diastolic blood pressure at rest was significantly lowered
with benazepril as compared with placebo. Similar findings
have been reported (30.32) with other angiotensin-
converting enzyme inhibitors. Metoprolol OROS signifi-
cantly increased the time to the development of I mm ST
segment depression and blunted the heart rate both at rest
and during maximal exercise. Although significant treatment
effect on maximal exercise time, which is most probably due
to metoprolol OROS, was observed with analysis of vari-
ance. it failed to achieve statistical significance when con-
trasted with placebo. most probably because of an unbal-
anced study design. Systolic blood pressure was also blunted
at maximal exercise. resulting in a lower rate-pressure
product as compared with placebo. Diastolic blood pressure
at rest was significantly lower on metoprolol OROS as
compared with placebo. Similar findings have been observed
(22.36-38) with other beta-blockers. Subjective variables.
such as number of anginal attacks and sublingual nitroglyc-
erin consumption. were reduced by metoprolol OROS alone.
Effects of benazepril and metoprolol OROS on ambulatory
ECG monitoring. Only metoprolol OROS was able to blunt
the heart rate significantly throughout the 24 h ambulatory
ECG monitoring period. Similar findings have been reported
(38.39) with propranolol. The number of episodes of ST
segment depression and total ischemic burden (duration of
ST depression) were reduced significantly by metoprolol
OROS. Similar findings have been reported (38-43) with
other beta-blockers. including the standard formulation of
metoprolol and calcium antagonists. Benazepril was also
able to reduce the number of episodes and duration of ST
segment depression as compared with placebo. However,
the change in ischemic burden in patients treated with
benazepril was not statistically significantly different from
those treated with placebo. but the size of the mean differ-
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ence does appear to be clinically significant and relevant. If
a few more patients had been studied, statistical significance
would have been achieved. Moreover, if one examines the
effect of double-blind placebo on ischemic burden or epi-
sodes of ST segment depression as compared with single-
blind placebo (Fig. 3), there are no relevant differences (209
episodes during the single-blind placebo run-in and 221
during double-blind placebo randomized). Similarly, dura-
tion of ischemia was 1,464 min during the single-blind
placebo run-in and 1,549 min during double-blind placebo
randomized. Therefore, one can confidently say that the
changes observed are real treatment effects and not placebo
or variability effects. We performed ambulatory monitoring
for only 24 h for practical reasons instead of 48 h, which
could have been more informative.
In this study, 97% of the ischemic episodes were silent
and our findings with benazepril indicate that this class of
drugs might be beneficial in silent myocardial ischemia. It is
difficult to speculate on the exact mechanisms of action.
However, the alterations in vasomotor tone due to suppres-
sion of angiotensin II, as well as a sympatholytic action of
benazepril, might well playa role in reducing ambulatory as
opposed to exercise-induced ischemia. Second, benazepril
failed to alter the systolic blood pressure and rate-pressure
product at maximal exercise. thereby suggesting that myo-
cardial oxygen demand. which is one of the predictors for
improving exercise-induced ischemia, was not reduced.
When both benazepril and metoprolol OROS were com-
bined, no further benefit was observed. although a tendency
to improve further was noticed in some of the measured
variables, It was also noteworthy that when two classes of
drugs were combined, the efficacy of metoprolol OROS was
maintained and did not impair any of the measured variables
of exercise testing and ambulatory ECG monitoring.
Conclusions. The results of this study suggest that
benazepril is well tolerated by patients with chronic stable
angina. Benazepril did not produce any clinical benefit in
exercise-induced ischemia and other angiotensin-converting
enzyme inhibitors have also been ineffective in studies in
normotensive patients with stable angina pectoris. However.
benazepril does reduce silent myocardial ischemia. although
not to a statistically significant degree; but the magnitude of
the reduction as compared with placebo is such that the
difference appears to be clinically significant and relevant.
Furthermore, when given in association with the beta-
blocker metoprolol OROS, no deleterious effects were ob-
served nor did it impair the anti-ischemic effects of meto-
prolol OROS, The anti-ischemic effects of metoprolol
OROS, which are similar to those reported with other
beta-blockers, are confirmed. Further clinical studies are
needed to establish the role of angiotensin-converting en-
zyme inhibitors in silent myocardial ischemia in different
groups of patients.
We are indebted to Gunther H. Mehring. PhD for the statistical analysis and
Mariella Reitano for typing the manuscript.
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